{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:59:32Z","timestamp":1767945572692,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease-related liver fibrosis is linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD); however, its impact on patients with prediabetes remains unclear. The aim of our study was to investigate the associations between ASCVD and three noninvasive liver fibrosis scores, including the fibrosis-4 index (FIB-4), nonalcoholic fatty liver disease fibrosis score (NFS), and aspartate aminotransferase-to-platelet ratio index (APRI), in middle-aged and older patients with prediabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, a total of 7,409 patients with prediabetes aged 40 to 80 years were classified into two groups based on their ASCVD statuses. Logistic regression analysis was performed to explore the relationships between liver fibrosis scores and ASCVD. Restricted cubic spline (RCS) curves were employed to explore potential nonlinear relationships. The performances of the liver fibrosis scores were compared using receiver operating characteristic (ROC) curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Noninvasive liver fibrosis scores, including FIB-4, NFS, and APRI values, were independently associated with an increased likelihood of having ASCVD in middle-aged and older patients with prediabetes. After adjusting for confounding factors, the patients in the high-risk FIB-4, NFS, and APRI groups had 1.5, 2.6, and 1.5 times the odds of ASCVD, respectively, compared with those in the low-risk groups, with odds ratios and 95% confidence intervals of 1.497 (1.089\u20132.055) for FIB-4 (P\u00a0=\u00a00.013), 2.632 (1.949\u20133.560) for NFS (P &amp;lt; 0.001), and 1.483 (1.092\u20132.002) for APRI (P\u00a0=\u00a00.011). RCS analysis revealed a nonlinear positive correlation between FIB-4 and ASCVD, whereas the relationships between NFS and ASCVD and between APRI and ASCVD were approximately linear. In the ROC curve analysis, both FIB-4 and NFS exhibited area under the curve values exceeding 0.7 in detecting individuals with ASCVD, whereas APRI was a relatively poor discriminator of ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Liver fibrosis assessed via noninvasive indices was significantly positively associated with an increased risk of ASCVD in middle-aged and older patients with prediabetes, thereby underscoring the value of liver fibrosis scores as reliable indicators for identifying the presence of ASCVD in individuals with prediabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1712481","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:37Z","timestamp":1767940777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver fibrosis assessed via noninvasive liver fibrosis scores is associated with atherosclerotic cardiovascular disease in middle-aged and older patients with prediabetes"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letong","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingru","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60283-9","article-title":"Prediabetes: a high-risk state for diabetes development","volume":"379","author":"Tabak","year":"2012","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12933-023-01982-6","article-title":"Prevalence of atherosclerosis in individuals with prediabetes and diabetes compared to normoglycaemic individuals-a Swedish population-based study","volume":"22","author":"Ostgren","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2297","article-title":"Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis","volume":"370","author":"Cai","year":"2020","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dca24-0012","article-title":"Associations of diabetes and prediabetes with mortality and life expectancy in China: a national study","volume":"47","author":"Tian","year":"2024","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15359","article-title":"Impact of liver fibrosis score on the incidence of stroke: a cohort study","volume":"42","author":"Xiong","year":"2022","journal-title":"Liver Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2022.07.016","article-title":"FIB-4 predicts MACE and cardiovascular mortality in patients with nonalcoholic fatty liver disease","volume":"38","author":"Chew","year":"2022","journal-title":"Can J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15387","article-title":"Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes","volume":"36","author":"Chun","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B10","unstructured":"Body Mass Index\n          \n          \n          \n          2025"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000596","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"B12","first-page":"62","volume-title":"ISO 15189:2022 \u2014 Medical laboratories \u2014 Requirements for quality and competence","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"LoMonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/life12081189","article-title":"New insights into non-alcoholic fatty liver disease and coronary artery disease: the liver-heart axis","volume":"12","author":"Cazac","year":"2022","journal-title":"Life (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/life14040473","article-title":"Platelet, antiplatelet therapy and metabolic dysfunction-associated steatotic liver disease: a narrative review","volume":"14","author":"Boccatonda","year":"2024","journal-title":"Life (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155179","article-title":"Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease","volume":"130","author":"Baars","year":"2022","journal-title":"Metabolism"},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.pcad.2023.03.002","article-title":"Coronary artery calcium, hepatic steatosis, and atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus: results from the Dallas heart study","volume":"78","author":"Khawaja","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1244405","article-title":"Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease","volume":"14","author":"Semmler","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166763","article-title":"The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): looking for the culprit","volume":"1870","author":"Fabris","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10625-7","article-title":"The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes","volume":"18","author":"Ma","year":"2024","journal-title":"Hepatol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16016","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002462","article-title":"The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"34","author":"Yi","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e14061","DOI":"10.1111\/eci.14061","article-title":"Liver fibrosis is associated with an increased risk of non-fatal myocardial infarction","volume":"53","author":"Riccio","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15660","article-title":"Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"51","author":"Henson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejim.2022.05.004","article-title":"Low serum albumin: a neglected predictor in patients with cardiovascular disease","volume":"102","author":"Manolis","year":"2022","journal-title":"Eur J Intern Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154874","article-title":"Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes","volume":"124","author":"Li","year":"2021","journal-title":"Metabolism"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1712481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:39Z","timestamp":1767940779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1712481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":30,"alternative-id":["10.3389\/fendo.2025.1712481"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1712481","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1712481"}}